Cover Image
Market Research Report

Company Analysis: AbbVie

Published by Datamonitor Healthcare Product code 603904
Published Content info 40 Pages
Delivery time: 1-2 business days
Price
Back to Top
Company Analysis: AbbVie
Published: November 27, 2017 Content info: 40 Pages
Description

Updated analysis and forecasts based on Q3 2017 company-reported sales.

PharmaVitae explores AbbVie's prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016-26.

Snapshot:

Overview - AbbVie looks to offset long-term declines in Humira sales with emerging pipeline portfolio.

Mid-term outlook - Humira will begin to decline in sales from 2019 due to European biosimilar entry in Q4

2018. Long-term outlook - Pipeline drugs including Venclexta, elagolix, and Rova-T will offset declines in Humira, with the company's sales set to grow 1.7% by

2026. Events - FDA approval decision on Mavyret in Q3

2017. Highlights:

AbbVie has boosted its oncology exposure with a $21bn deal for Pharmacyclics and $5.8bn takeover of Stemcentrx.

AbbVie's acquisition of Shire was terminated due to US tax regulation changes.

AbbVie seeks to lessen dependency on Humira.

AbbVie will reap rewards from expansion into oncology.

Mavyret approval will take market share from Gilead's HCV products.

Analysis structure:

Company context

How is AbbVie strategically poised out to 2026?

What are AbbVie's key strengths, weaknesses, opportunities, and threats?

What are AbbVie's key catalysts over the next four quarters?

Facts and figures

What is AbbVie's forecasted sales performance out to 2026?

What is the revenue trajectory of AbbVie's current top 10 products out to 2026?

Which therapy areas will experience the largest growth and decline?

What are the portfolio weightings of AbbVie based on the lifecycle of products?

Key therapy areas

Immunology and inflammation | Oncology | Infectious diseases

Why will specific therapy areas experience the largest growth and decline?

What are the detailed competitive dynamics at play in AbbVie's important therapeutic markets?

How is AbbVie adapting strategically to internal and external headwinds?

Table of Contents
Product Code: DMKC0135089

TABLE OF CONTENTS

EXECUTIVE SUMMARY

  • Q3 2017
  • What were the highlights of AbbVie's Q3 earnings call?
  • Will AbbVie grow through Humira's patent expiries?
  • Q3 2017 regulatory update

COMPANY CONTEXT

  • AbbVie split from Abbott
  • Humira
  • Amgen-AbbVie settlement
  • Future revenue streams
  • Commercial strategy
  • AbbVie's SWOT analysis
  • AbbVie's key events and catalysts

FACTS AND FIGURES

  • AbbVie's prescription pharma sales outlook
  • AbbVie's regional pharma sales outlook
  • AbbVie's therapy area dynamics
  • AbbVie's sales by therapy area
  • AbbVie's top 10 products over 2016-26
  • AbbVie's growth drivers and resistors
  • AbbVie's portfolio lifecycle analysis
  • AbbVie's M&A history

KEY THERAPY AREAS

  • Immunology and inflammation
  • Oncology
  • Infectious diseases

BIBLIOGRAPHY

LIST OF FIGURES

  • Figure 1: AbbVie's prescription pharmaceutical sales ($m) and growth rate (%), 2013-26
  • Figure 2: AbbVie's therapy area dynamics, 2016-26
  • Figure 3: AbbVie's current top 10 products sales ($m), 2016-26
  • Figure 4: AbbVie's launch/core/expiry portfolio configuration, 2016-26

LIST OF TABLES

  • Table 1: AbbVie's prescription pharmaceutical sales by region ($m), 2016-26
  • Table 2: AbbVie's sales by therapy area ($m), 2016-26
  • Table 3: AbbVie's key products, 2016-26
  • Table 4: AbbVie's sales by launch, core, and expiry portfolio ($m), 2016-26
  • Table 5: AbbVie's key merger and acquisition deals, 2001-16
  • Table 6: AbbVie's immunology and inflammation portfolio sales, by product ($m), 2016-26
  • Table 7: AbbVie's oncology portfolio sales, by product ($m), 2016-26
  • Table 8: AbbVie's infectious diseases portfolio sales, by product ($m), 2016-26
Back to Top